Q4 2021 vs. Q4 2020 Restated Net Sales New Segment Presentation Less: Impact Less: Impact of Foreign of Recent Q4 Q4 As Reported Currency Operational Acquisitions / Organic (in millions) 2021 2020 Basis Fluctuations Basis Divestitures Basis ENDOSCOPY $ 558 $ 515 8.3 % (1.5) % 9.8 % — % 9.8 % UROLOGY 441 376 17.2 % (0.8) % 18.0 % 9.2 % 8.7 % NEUROMODULATION 244 232 5.2 % (0.6) % 5.8 % — % 5.8 % MEDSURG 1,243 1,123 10.6 % (1.1) % 11.7 % 3.1 % 8.6 % ICTx 575 520 10.7 % (2.1) % 12.8 % — % 12.8 % WATCHMAN 233 65 257.9 % (0.5) % 258.4 % — % 258.4 % CARDIAC RHYTHM MANAGEMENT 514 451 14.0 % (1.5) % 15.5 % 11.0 % 4.5 % ELECTROPHYSIOLOGY 100 85 18.1 % (2.8) % 20.9 % 5.3 % 15.6 % CARDIOLOGY 1,422 1,120 27.0 % (1.8) % 28.7 % 4.8 % 23.9 % PERIPHERAL INTERVENTIONS 462 429 7.6 % (1.4) % 9.0 % — % 9.0 % CARDIOVASCULAR 1,884 1,549 21.6 % (1.7) % 23.3 % 3.5 % 19.8 % 3,127 2,673 17.0 % (1.4) % 18.4 % 3.3 % 15.1 % † OTHER — 36 (100.0) % — % (100.0) % — % (100.0) % WORLDWIDE NET SALES $ 3,127 $ 2,708 15.4 % (1.4) % 16.9 % 1.8 % 15.1 % 30 Q4 2022 Financial & Operational Highlights | February 1, 2023